Literature DB >> 19080891

[Diagnosis and treatment of livedo reticularis on the legs].

C Herrero1, A Guilabert, J M Mascaró-Galy.   

Abstract

The term livedo reticularis refers to a reddish-violet reticular discoloration of the skin that mainly affects the limbs. It is caused by an interruption of blood flow in the dermal arteries, either due to spasm, inflammation, or vascular obstruction, and is associated with diseases of varying etiology and severity. To establish the cause of livedo reticularis, it is essential to determine its course (chronic, acute, or fulminant), the presence of other cutaneous signs such as nodules, retiform purpura or necrosis, and the possible association of general symptoms or laboratory findings that suggest a particular systemic process. The aim of this review is to describe the diagnosis and treatment of the disease.

Entities:  

Mesh:

Year:  2008        PMID: 19080891

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  5 in total

1.  Livedo reticularis and related disorders.

Authors:  Steven M Dean
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

2.  Livedo reticularis heralding hypercalcaemia of malignancy.

Authors:  Deepak Sundriyal; Naveen Kumar; Gaurav Kumar; Meenu Walia
Journal:  BMJ Case Rep       Date:  2014-05-15

3.  Livedo reticularis in type 2 lepra reaction: A rare presentation.

Authors:  Kikkeri Narayanasetty Naveen; Sharatchandra Bhimrao Athanikar; Spandana Prakash Hegde; Vidisha Sharatchandra Athanikar
Journal:  Indian Dermatol Online J       Date:  2014-04

4.  Cutaneous manifestations of systemic lupus erythematosus.

Authors:  Luís Uva; Diana Miguel; Catarina Pinheiro; João Pedro Freitas; Manuel Marques Gomes; Paulo Filipe
Journal:  Autoimmune Dis       Date:  2012-07-25

5.  Amantadine-induced livedo reticularis--Case report.

Authors:  Maria Victória Quaresma; Ana Carolina Dias Gomes; Aline Serruya; Dâmia Leal Vendramini; Lara Braga; Alice Mota Buçard
Journal:  An Bras Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.